Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M

INCYTE CORP

2022-Q3 EPS reported $1.40 revenue$2,467,935,000

Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).
GAAP diluted EPS $0.50 (vs $0.82 YoY); Non-GAAP diluted EPS $0.60 (vs $1.18).
Jakafi FY22 guidance low end raised to $2.38-2.40B; other Hem/Onc rev guidance lowered to $200-210M on FX.
Pending acquisition of Villaris (auremolimab anti-IL-15Rβ mAb) for vitiligo; clinical start 2023.
Pipeline: once-daily ruxolitinib XR PDUFA Mar 23, 2023; axatilimab cGVHD results mid-2023; povorcitinib Ph3 HS end-2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INCYTE CORP reported third fiscal quarter ended September 30, 2022 results: revenue $713 million. Guidance raised.

Period: third fiscal quarter ended September 30, 2022
Revenue: $713 million
Guidance: raised
Result: reported results

Exact text from the filing

Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura TM (ruxolitinib) cream net product revenues – Jakafi net product rev enues of $620 million in Q3’22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion

View on SEC.gov

Browse all earnings releases →

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0000879169-22-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.